Cargando…

Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.

Doxorubicin (DXR) has a positive inoculum effect and penetrates poorly into the core of multicellular tumour spheroids (MTS). Cis-platin (DDP) displays neither of these characteristics. We evaluated whether combining these 2 agents would influence the cell kill effect at a tumour mass level. MTS wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohno, N., Ohnuma, T., Kaneko, M., Holland, J. F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1988
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246593/
https://www.ncbi.nlm.nih.gov/pubmed/3179185
_version_ 1782150804430389248
author Kohno, N.
Ohnuma, T.
Kaneko, M.
Holland, J. F.
author_facet Kohno, N.
Ohnuma, T.
Kaneko, M.
Holland, J. F.
author_sort Kohno, N.
collection PubMed
description Doxorubicin (DXR) has a positive inoculum effect and penetrates poorly into the core of multicellular tumour spheroids (MTS). Cis-platin (DDP) displays neither of these characteristics. We evaluated whether combining these 2 agents would influence the cell kill effect at a tumour mass level. MTS were produced from a PC-10 squamous lung carcinoma cell line. MTS were exposed to either drug first for 1 h with different intervals between exposure. Cells were then trypsinized to a single cell suspension and subjected to clonogenic assay. Combination effects were analyzed by median effect plot analysis. The more MTS ml-1 medium, the lower the cell kill effect of DXR. Simultaneous exposure to the 2 drugs was synergistic. DXR exposure first followed by DDP was less efficacious than, or the same as, the simultaneous exposure. In contrast, DDP followed by DXR was more efficacious with the best cell kill at a 1 h interval between each drug. This phenomenon was observed even at non-toxic doses of DDP. The fluorescent microscopic study of DXR indicated that prior exposure of MTS to DDP resulted in increased DXR penetration into the MTS core leading to heightened synergism with this sequence. These data suggest that the proper combination of DXR plus DDP should be in sequence with DDP first. Clinical, toxicological and pharmacological trials of DDP administration first, followed by DXR, are warranted. IMAGES:
format Text
id pubmed-2246593
institution National Center for Biotechnology Information
language English
publishDate 1988
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22465932009-09-10 Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. Kohno, N. Ohnuma, T. Kaneko, M. Holland, J. F. Br J Cancer Research Article Doxorubicin (DXR) has a positive inoculum effect and penetrates poorly into the core of multicellular tumour spheroids (MTS). Cis-platin (DDP) displays neither of these characteristics. We evaluated whether combining these 2 agents would influence the cell kill effect at a tumour mass level. MTS were produced from a PC-10 squamous lung carcinoma cell line. MTS were exposed to either drug first for 1 h with different intervals between exposure. Cells were then trypsinized to a single cell suspension and subjected to clonogenic assay. Combination effects were analyzed by median effect plot analysis. The more MTS ml-1 medium, the lower the cell kill effect of DXR. Simultaneous exposure to the 2 drugs was synergistic. DXR exposure first followed by DDP was less efficacious than, or the same as, the simultaneous exposure. In contrast, DDP followed by DXR was more efficacious with the best cell kill at a 1 h interval between each drug. This phenomenon was observed even at non-toxic doses of DDP. The fluorescent microscopic study of DXR indicated that prior exposure of MTS to DDP resulted in increased DXR penetration into the MTS core leading to heightened synergism with this sequence. These data suggest that the proper combination of DXR plus DDP should be in sequence with DDP first. Clinical, toxicological and pharmacological trials of DDP administration first, followed by DXR, are warranted. IMAGES: Nature Publishing Group 1988-09 /pmc/articles/PMC2246593/ /pubmed/3179185 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Kohno, N.
Ohnuma, T.
Kaneko, M.
Holland, J. F.
Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
title Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
title_full Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
title_fullStr Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
title_full_unstemmed Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
title_short Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
title_sort interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246593/
https://www.ncbi.nlm.nih.gov/pubmed/3179185
work_keys_str_mv AT kohnon interactionsofdoxorubicinandcisplatininsquamouscarcinomacellsinculture
AT ohnumat interactionsofdoxorubicinandcisplatininsquamouscarcinomacellsinculture
AT kanekom interactionsofdoxorubicinandcisplatininsquamouscarcinomacellsinculture
AT hollandjf interactionsofdoxorubicinandcisplatininsquamouscarcinomacellsinculture